Dolasetron: A new option for nausea and vomiting

Journal of the American Animal Hospital Association

Volumn 36, Issue 6, 2000, Pages 481-483

  Ogilvie, Gregory K ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; AZASETRON; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; TROPISETRON;

CANCER PATIENT; CAT; DOG; DRUG EFFECT; DRUG EFFICACY; ENTEROCHROMAFFIN CELL; HUMAN; NAUSEA; NONHUMAN; QUALITY OF LIFE; RECEPTOR AFFINITY; SHORT SURVEY; TREATMENT INDICATION; VOMITING;

EID: 0033758704     PISSN: 05872871     EISSN: None     Source Type: Journal    
DOI: 10.5326/15473317-36-6-481     Document Type: Short Survey

References (8)

1. Sanwald-Ducray P, Dow J. Prediction of the pharmacokinetic parameters of reduced-dolasetron in man using in vitro-in vivo and interspecies allometric scaling. Xenobiotica 1997;27(2):189-201.
2. Dow J, Francesco GF, Berg C. Comparison of the pharmacokinetics of dolasetron and its major active metabolite, reduced dolasetron, in the dog. J Pharm Sci 1996;85(7):685-9.
3. Philip BK, McLeskey CH, Chelly JE, et al. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group. J Clin Anesth 2000;12(1):1-8.
4. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000;18(2):163-73.
5. Zarate E, Watcha MF, White PF, et al. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. Anesth Analg 2000;6:1352-8.
6. Anastasia PJ. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy. Oncol Nurs Forum 2000;27(3):483-93.
7. Fauser AA, Pizzocaro G, Schueller J, et al. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 2000;8(1):49-54.
8. Kovac A, Mingus M, Sung YF, Neary M. Reduced resource utilization in patients treated for postoperative nausea and vomiting with dolasetron mesylate. MCPR44 Study Group. J Clin Anesth 1999;11(3):235-41.